Balchem has delivered solid returns in recent years, which puts a spotlight on whether the current share price lines up with the cash the business is expected to generate. With the stock now trading around US$174.60, the key issue is how that market value compares to what a Discounted Cash Flow (DCF) view of its future cash streams suggests.
- Over the past 3 years Balchem has returned 46.9%, putting real weight behind the question of whether that performance is already fully reflected in the valuation.
- Record sales, earnings and cash generation, alongside a new US$650m credit facility and ongoing buybacks, can influence how investors think about the timing and durability of Balchem's future cash flows.
- If you'd rather focus on earnings, this one's for you. See why Balchem's 32.5x P/E tells a different valuation story.
The stock's next move may depend on whether Balchem's current price is supported by the intrinsic value suggested by its cash flows under a Discounted Cash Flow (DCF) approach.
If you want other ideas where the focus is on valuation, a targeted stock screen can help you start that research with 34 high quality undervalued stocks.
Is Balchem Still Cheap on Cash Flow?
The Discounted Cash Flow (DCF) approach here takes Balchem's expected future free cash generation and discounts it back to today’s dollars. Latest twelve month free cash flow sits at about $180.2 million, with the model assuming that this cash figure grows over time rather than shrinking.
Those projections reach just over $230 million of free cash flow by 2028, then continue to edge higher in the following years. This is more in line with a steady compounder than a turnaround story. Record Q3 2026 sales and earnings, backed by a $650 million credit facility and ongoing buybacks, help explain why the DCF output points to an intrinsic value that is modestly above the current $174.60 share price. Find out what Balchem could be worth using our Discounted Cash Flow (DCF) estimate.
The Balchem Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the Balchem valuation puzzle leaves off by spelling out which expectations for growth, profitability and earnings would need to hold for the stock to be worth meaningfully more or less than today. Each Narrative ties a fair value to a particular storyline about Balchem's potential catalysts and key risks so you can track over time which version of the future is actually playing out.
One of the top community narratives on Balchem: roughly fairly valued
"Capacity investments, including the state of the art microencapsulation facility in New York and additions across Human, Animal and Plant Nutrition…"
Discover why this Narrative puts Balchem at roughly fairly valued.
One more Balchem check that belongs beside the price tag
Before you move on from Balchem based only on the cash flow maths and current share price, it is worth examining who is steering the business and how their rewards line up with your interests. See who runs Balchem and how they are paid.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com